On August 14, 2025 NanoCell Therapeutics, Inc. ("NanoCell"), a biotechnology company developing a non-viral, DNA-based in vivo gene therapy platform, reported it has been awarded a Eurostars Grant from the European Union (EU) through the Horizon Europe program and the Eureka Network (Press release, NanoCell Therapeutics, AUG 14, 2025, View Source [SID1234655310]). The grant will fund NanoCell’s QUIET-CAR project, which is focused on the development of targeted lipid nanoparticles containing novel immune-quiet DNA constructs for in vivo CAR-T therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This funding validates our innovative approach to non-viral gene therapy and will accelerate our QUIET-CAR project toward delivering safer, more accessible CAR-T treatments for patients with cancer and autoimmune disease," said Dr. Maurits Geerlings, CEO and President of NanoCell Therapeutics. "Being selected and top ranked among over 120 submissions in Europe’s most competitive SME funding program demonstrates the transformative potential of our technology platform."
The QUIET-CAR project is a collaboration between NanoCell and CPTx, a biotech company developing advanced medicine using AI-supported molecular design and programmable single-stranded DNA fabrication supported by gxstrands. Eurostars, part of the European Partnership on Innovative SMEs and supported by Horizon Europe, is a premier funding initiative designed to accelerate transnational innovation. With participation from 37 countries, the program rigorously selects only the most promising technological breakthroughs, evaluated by independent experts.
NanoCell acknowledges the support of Amsterdam-based Catalyze for the successful preparation of this grant.